Subscribe Now!

Neuland Labs Ltd - Q3FY21 Result Update

-
Neuland Labs Ltd Q3FY21 Result Update
Twitter Handle: @shuchi_nahar 
Link to Company Overview of Neuland Labs in detail: https://myweekendspot.blogspot.com/2020/09/neuland-labs-company-snapshot.html
The company has announced consecutive another strong quarter of top-line and bottom-line performance. The revenue at Rs.245.6 crores was a 20% improvement over the corresponding quarter of the last fiscal while the margins have shown an upward trajectory and closed at 19.0%. This was driven by growth across the GDS and CMS verticals. The company remains confident of its long-term growth aspirations as well as its margin resilience. 
• Total income increased by 20.0% in Q3FY21 on account of secular growth in GDS and CMS.
• Prime segment continues growth led by Levetiracetam and Mirtazapine.
• Speciality business had a stable quarter led by Deferasirox and Dorzolamide.
• CMS business witnessed growth in scale-up projects and higher projects coming up for validation.
• Two APIs shipped from Unit III.
• Filed DMF for Donepezil Base with USFDA.
• EBITDA margin increased by 480 bps from 14.2% to 19.0% in Q3FY21.
• Increase in PBT margins by 540 bps and PAT margins by 550 bps.

Revenue in Cr
Source: Q3FY21 Investor Presentation
Number of Active CMS Projects
Source: Q3FY21 Investor Presentation
CMS the business has shown a good momentum while the GDS also continues to play an important part in the growth. The driver of this quarter’s CMS uptick has been the strong performance from the scale-up projects which have contributed to the revenues. Unit 3 has started commercial production and the company is currently shipping out 2 API’s from this facility. It's expected that Unit 3 to be a major driver of our growth going forward. 
Regulatory Filings by the Company till Date in various Countries
Source: Q3FY21 Investor Presentation
Chart Showing the Regulatory Filings done by Company
  • 898+ DMFs filed
  • 300+ API processes developed
  • 204+ patents filed
  • Received USPTO patent for improved process synthesis of Paliperidone Palmitate
  • Support for multiple APIs each year in Phase 2 and Phase 3 clinical candidates
Capacity Expansion Plans to cater opportunities
So currently for the year 2021, the company is roughly at around 80 crores of investments and they have a plan to basically evaluate certain CAPEX proposals that are in the pipeline in the range of 50 to 60 crores in this year. So it depends how a particular molecule looks like if it makes the attractive business investment. For the next year also, the company has a similar kind of investment plans because the business is looking attractive for new propositions.

Future Outlook
Company has already developed peptides like Linaclotide. The company is efficiently  working on peptides like Liraglutide and Semaglutide and these are having huge commercial value going forward. These peptides being fairly complex in nature, the timelines for development for filing a DMF are longer.

Typical small molecules take anywhere from 3 to 9 months to file a DMF whereas the complex peptide-like Liraglutide or Semaglutide could take 2-2.5 years. But given that the opportunity is fairly large and the company is excited about these molecules and hopefully, the company is having few interesting partnerships on the generic peptide side. 

Disclaimer: The information provided on Shuchi Nahar’s Weekend Blog is for educational purposes only. The articles may contain external links, references, and a compilation of various publicly available articles. Hence all the authors are given due credit for the same. All copyrights and trademarks of images belong to their respective owners and are used for Fair Educational Purpose only.

Twitter Handle: @shuchi_nahar

Comments

Post a Comment

Most Favorite Reads!

Ethanol - Demand, Production, Opportunities & Production Projections (Part-2)

-
Image
Rapid Increase in Ethanol Production Capacity Twitter Handle: @shuchi_nahar Two Different types of processes  to produce Ethanol To produce 684 crore liters of ethanol by the sugar industry by 2025-26, sugarcane equivalent to 60 LMT of surplus sugar would be diverted to ethanol. In the current sugar season, 2020-21 more than 20 LMT of sugar is estimated to be diverted. To produce 666 crore liters of ethanol/ alcohol from food grains by 2025-26, about 165 LMT of food grains would be utilized. At present damaged food grain availability is around 40 lakh tons in the country. In 2020-21 approximately 20 lakh ton maize is surplus FCI Rice is also sufficient in stock (266 LMT) and it will continue to remain robust as procurement of paddy/rice at MSP continues at expected levels. The country is producing sufficient food grains and sugar to meet the requirement for ethanol. Molasses-based distilleries have also been offered interest subvention to convert them to dual feed, to convert both
Read more

Ethanol - Demand, Market Size, Opportunities & New Goverment Policies (Part-2)

-
Image
Ethanol production capacities, impact on Farmers, and Government Plans Twitter Handle: @shuchi_nahar Ethanol was rarely discussed in the country about 7-8 years ago. But now ethanol has become one of the major priorities of 21st century India. The focus on ethanol is having a better impact on the environment as well as on the lives of farmers. India’s requirement of ethanol for petrol blending will increase from 173 crore liters in 2019-20 to 1,016 crore liters in 2025-26. To enable the rollout of ethanol production across India, ethanol may be supplied from surplus to deficit states based on the requirements to ensure uniform availability of ethanol blends in the country. To achieve the Modi Administration’s E-20 blending goal by ethanol supply year (ESY) (December-November) 2025, India would need to procure approximately 11 billion liters (BL) of ethanol for blending with petroleum. As of November 2021, India’s concentrated ethanol production capacity totaled slightly above 6 bi
Read more

Ethanol - Demand, Market Size, Opportunities & New Goverment Policies (Part-1)

-
Image
Ethanol - The next big tailwind story Twitter Handle: @shuchi_nahar Introduction Ethanol , also called ethyl alcohol, drinking alcohol, or simply alcohol is simple alcohol that is often abbreviated as EtOH. Ethanol production in India is mainly dominated by sugary feedstock, and C-heavy molasses available from sugar mills. Ethanol produced by fermentation of renewable food crops such as sugarcane, maize, wheat, sorghum, beet, and other starches is called bioethanol, and it is the eco-friendly alternative biofuel. The product is primarily used as a solvent in various industries such as: In addition, ethanol is gaining popularity as an efficient alternative fuel. It has significant penetration in the major end-use industries such as automotive, foods and beverages, chemicals, personal care and cosmetics, and pharmaceuticals. According to the reports, the global ethanol market is projected to grow at a robust CAGR of 4.5% to reach USD 117 Billion by the end of 2027. The primary factors fa
Read more

Nutraceuticals - The Next Gem of Healthcare Sector

-
Image
     Nutraceuticals - The Next Gem of Healthcare Sector Shuchi.P.Nahar Twitter: shuchi_nahar What is Nutraceuticals? The term ‘nutraceuticals’ was firstly used in the late 1980s to describe food products that have a medicinal benefit. This fast-growing sector includes functional foods (such as vitamin-enriched products), nutritional supplements, sport drinks, and medically formulated foods.  Nutraceuticals and its Division Figure 1: The diagram showing the various divisions of Nutraceuticals  Scope Nutraceuticals is expected to play a central role in preventative healthcare. The logic seems simple - an ageing population gives rise to lifestyle-related diseases, whose impact can be lessened by making healthier choices earlier in life. This convergence of medicine, food and technology is likely to create a battleground in which food and pharma companies compete for dominance of the sector. Successful companies will have to hit the bullseye in six main areas: technology, product strategy,
Read more

Laurus Labs - Result Update Q4FY21 & Full Year FY21

-
Image
Laurus Labs - Result Update Q4FY21 & Full Year FY21 Twitter Handle: @shuchi_nahar Laurus Labs Limited on 30th April 2021 announced its Q4FY21 and full-year results.  Laurus Lab performed extremely well consecutive in the 4th Quarter of FY21. The company did a robust growth in all three segments. Having a healthy order book for FY 22. Consolidated revenue for the quarter increased by 70% driven by growth in all the divisions. The company has been able to sustain its EBITDA margins, and profitability has also improved to Rs. 297 Crs. for the quarter. Generic API division showcased a robust growth of 61% YoY. Anti Viral segment recorded a robust growth of 70% YoY. Revenue Showcased a healthy growth of 102% YoY. The growth was led by higher LMIC Market volumes and increased volumes from North America and EU Commenced marketing of in-licensed products in the USA to leverage front-end capabilities. Custom Synthesis division recorded a strong growth of 35% YoY. Capacity Expansion – To
Read more